Table 3 Reasons for discontinuation during the study
Reason for discontinuation, n(%) | Placebo | OROS MPH | |
|---|---|---|---|
(n= 97) | 54 mg/day | 72 mg/day | |
(n= 87) | (n= 92) | ||
Discontinued | 29 (29.9) | 32 (36.8) | 37 (40.2) |
Adverse event | 2 (2.1) | 15 (17.2) | 19 (20.7) |
Lack of efficacy | 14 (14.4) | 1 (1.1) | 4 (4.3) |
Noncompliance | 3 (3.1) | 5 (5.7) | 5 (5.4) |
Consent withdrawal | 4 (4.1) | 2 (2.3) | 3 (3.3) |
Loss to follow-up | 5 (5.2) | 1 (1.1) | 0 |
Sponsor’s decision | 0 | 2 (2.3) | 0 |
Ineligibility to continue the study | 0 | 1 (1.1) | 1 (1.1) |
Other | 1 (1.0) | 5 (5.7) | 5 (5.4) |